Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Claiming that bispecific adverse events management is “pretty straightforward” illustrates the fundamental difference between conventional oncology and myeloma survivors.
Conventional oncology thinks short-term- as in 5-10 years short-term. Evidence of this is the Siracusa Charter doing somersaults trying to determine how to use the word cure in cancer treatment.
Let me go on record as saying that conventional myeloma oncology should be congratulated for dramatically increasing the average life expectancy of newly diagnosed myeloma patients. When I was diagnosed with myeloma in 1994, the average life expectancy of a NDMM patient was 3-5 years. This average has increased to 8-10 years.
The issue I have with saying that bispecific adverse events management is “pretty straightforward” is that there is no way of knowing if the serious side effects of bispecifics in myeloma might be long-term.
And no, conventional myeloma therapies are not why I’m alive 30 years after my MM diagnosis.
It’s a combination of hubris and ignorance to think that common adverse events like the ones discussed in the article below will simply be temporary. Long-term effects will surely be prevalent if the myeloma patient lives. But that’s for another post.
If you are considering undergoing a bispecific therapy for a chance at another remission, I fully understand. However do not believe that bispecific adverse events management is straightforward.
Email me at David.PeopleBeatingCancer@gmail.com if you have any questions about short, long-term or late stage side effects of myeloma therapies.
Thank you,
“Following the first approval in 2022, bispecific antibody therapy has added to the triple- and penta-refractory multiple myeloma treatment landscape. With this, there are adverse events (AEs) that oncology nurses must be aware of following the administration of these agents.
During a recent Community Case Forum event, Donna Catamero, ANP-BC, OCN, CCRC, and colleagues discussed AE monitoring of patients being treated with 1 of the 3 available bispecific antibodies for relapsed/refractory myeloma:
“[Adverse events] can be predictable, depending on the drug we’re using,” Catamero, who is the associate director of the Multiple Myeloma Research Program at the Mount Sinai Health System in New York, NY, said. “[Immune effector cell-associated neurotoxicity syndrome (ICANS)] will typically follow a [cytokine release syndrome (CRS)] event, but we know that that can happen at any point. Cytopenia, [hypogammaglobulinemia], and then infections–I think that all goes hand in hand.”
ICANS (commonly referred to as “neurotoxicity”) and CRS are some of the more severe adverse events associated with bispecific antibody treatment. Catamero stressed that providers in the academic setting and the community setting should know how to approach AEs–especially as patients may start treatment in an academic or specialized institution and then move on to the community setting…
CRS management depends on the grade:
Similarly, ICANS treatment should also be grade-specific:
“Anything about the CRS and infections aside, which can be managed, the side effect profile [of bispecific antibody therapy] was actually pretty manageable, especially for people who have been through so much,” forum attendee, Patrick Spencer, RN, OCN, of Mount Sinai said. “They handle it very well, and it’s refreshing for them.”